Saxagliptin Review Deadline Pushed Back; Approval Chances Still Look Good
FDA is extending the user fee goal date for action on Bristol-Myers Squibb/AstraZeneca's DPP-4 inhibitor antidiabetic Onglyza (saxagliptin) to July 30
You may also be interested in...
Bristol-Myers Squibb and AstraZeneca will need to design a precedent-setting cardiovascular outcomes study for saxagliptin before the drug will be approved by the agency
Bristol and FDA need to agree on post-marketing cardiovascular outcomes trial for antidiabetic. Agency mum on efficacy and other safety issues.
Novo hopes the differing drug class and bigger Phase III trial will help diabetes drug get past heart-safety rules that tripped up the compound from Takeda.